DiaPrecise, A Phase II Open Label Study to evaluate the safety and feasibility of intralymphatic administration of Diamyd® in individuals at risk for Type 1 diabetes carrying the HLA DR3-DQ2 haplotype

Status

Recruiting

Phases

Phase 2

Study type

Interventional

Source

EU CTIS

Registry ID

CTIS2024-513350-30-00

Acronym

D/P2/22/8

Enrollment

Registered

2024-06-19

Start date

2024-07-09

Completion date

Unknown

Last updated

2025-11-24

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Type 1 diabetes mellitus

Brief summary

The primary endpoint in this study is to evaluate the feasibility and safety of two or three injections of Diamyd, administered into an inguinal lymph node.

Interventions

DRUGDiamyd

Eligibility

Sex/Gender

All

Age

0 Years to 17 Years

Design outcomes

Primary

Measure	Time frame
The primary endpoint in this study is to evaluate the feasibility and safety of two or three injections of Diamyd, administered into an inguinal lymph node.	—

Countries

Sweden

Outcome results

None listed

Source: EU CTIS · Data processed: Feb 4, 2026